Format

Send to

Choose Destination
J Clin Invest. 2008 Jun;118(6):1979-90. doi: 10.1172/JCI34359.

To kill a tumor cell: the potential of proapoptotic receptor agonists.

Author information

1
Genentech, South San Francisco, California 94080, USA. aa@gene.com

Abstract

Disturbances in mechanisms that direct abnormal cells to undergo apoptosis frequently and critically contribute to tumorigenesis, yielding a logical target for potential therapeutic intervention. There is currently heightened interest in the extrinsic apoptosis pathway, with several proapoptotic receptor agonists (PARAs) in development. The PARAs include the ligand recombinant human Apo2L/TRAIL and agonistic mAbs. Mechanistic and preclinical data with Apo2L/TRAIL indicate exciting opportunities for synergy with conventional therapies and for combining PARAs with other molecularly targeted agents. Novel molecular biomarkers may help identify those patients most likely to benefit from PARA therapy.

PMID:
18523647
PMCID:
PMC2396896
DOI:
10.1172/JCI34359
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center